Pluristem Therapeuitcs Inc. (NasdaqCM: PSTI; DAX: PJT) today announced that following its meeting with the Paul Ehrlich Institute (PEI), the German regulatory authority for advanced therapy products (ATP), the company is advancing toward designing two Phase IIb clinical trials for its placenta-derived cell therapy product, PLX-PAD, for the treatment of Critical Limb Ischemia (CLI) and Moderate-severe Claudication.

SUNRISE, Fla., May 28 /PRNewswire-FirstCall/ -- Bioheart, Inc., (OTC Bulletin Board: BHRT) announced today plans for establishing two Centers of Excellence in the Middle East to provide its cell therapy procedures to patients suffering from congestive heart failure (CHF) and peripheral arterial disease (PAD). Dr. Karl E. Groth, Chairman and CEO, and Peggy A. Farley, Chief Operating and Financial Officer, are now in that region holding discussions and performing site inspections.

John Naimi is accustomed to leading a life full of family, farm work and travel. But today, the 55-year-old walnut and almond farmer avoids playing with his nieces and nephews, has scaled back his business and stayed home while his wife traveled to Europe this past summer.

"If I walk too much, my foot becomes stiff. If I get a tiny cut, I know I'm going to have excruciating pain," says Naimi, who lives in San Jose when he is not at his farm in Gustine, Calif.

Principal Investigator Dr. Richard Powell to Present Interim Results From U.S. Phase 2b RESTORE-CLI Trial at the 2010 Vascular Annual Meeting(R) on June 11 in Boston, MA.

ANN ARBOR, Mich., May 3, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that positive interim results from the company's U.S. Phase 2b trial designated RESTORE-CLI has been accepted for presentation at this year's Vascular Annual Meeting® of the Society for Vascular Surgery. These promising interim results will be presented by Richard J. Powell, M.D., section chief of vascular surgery at the Dartmouth-Hitchcock Medical Center in Lebanon, NH and a principal investigator of the study.